Company Overview
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company based in the United States, focusing its product development on specific therapeutic formulations. The company's primary asset is PEDMARK, a sodium thiosulfate formulation specifically designed for the prevention of platinum-induced ototoxicity in pediatric cancer patients, which the firm sells through commercial channels. This entity functions within the broader Healthcare sector, specifically targeting the Biotechnology industry, where companies are typically engaged in the discovery, development, and commercialization of novel drugs and medical technologies. The company's market capitalization stands at $211.80M, while its trailing twelve-month revenue is $44.64M, and the employee count is listed as N/A. These valuation and revenue figures indicate that Fennec holds a mid-cap position within the biotechnology landscape, suggesting a scale that is significant enough to pursue commercialization but still relies heavily on the successful performance of its single product candidate to drive further growth and stability.
Financial Health
The company reported a revenue of $44.64M over the trailing twelve months, yet it recorded a net income of $-10,098,000 and an EBITDA of $-6,641,333 during the same period. The substantial gap between the $44.64M in revenue and the negative net income reveals a cost structure characterized by high operating expenses relative to sales, a common trait in commercial-stage biopharmaceutical companies before achieving widespread profitability. Regarding cash flow, the Free Cash Flow is listed as N/A, which implies that the company is currently in a cash-burning phase where capital expenditures and working capital requirements exceed the cash generated from operations. The balance sheet shows a cash position of $36.79M, while debt is listed as N/A, and the debt-to-equity ratio is also N/A. The absence of reported debt suggests a conservative balance sheet approach, relying primarily on equity and cash reserves to fund operations and growth initiatives. Liquidity is further supported by a Current Ratio of 6.34, indicating that the company holds significantly more current assets than current liabilities, providing a robust buffer against short-term obligations. Return on Equity stands at -69.1% and Return on Assets is -7.3%, metrics that reveal the company is currently diluting shareholder value and underutilizing its asset base to generate positive returns due to its pre-profitability status.
Valuation Assessment
Valuation metrics for the stock show a Trailing P/E ratio of N/A due to the negative earnings, whereas the Forward P/E is 6.61, implying that the market prices in significant future earnings growth relative to current profitability. The Price to Book ratio is 6.00, indicating that the stock trades at a substantial premium to its net asset value, which is typical for biotechnology firms with high growth potential and intangible assets. The Price to Sales ratio is 4.74, and the EV/EBITDA is -26.20; these alternative metrics suggest that the market is valuing the company based on revenue generation and future clinical or commercial milestones rather than current earnings power. The stock has traded between a 52-Week High of $9.92 and a 52-Week Low of $4.68, placing the current trading environment within a range that reflects significant volatility typical of small-cap biotech assets. The Beta value is 0.81, which suggests that the stock's price volatility is slightly lower than the broader market, meaning it may be less sensitive to general market fluctuations compared to a benchmark index.
Growth & Income
Revenue growth for the year-over-year period is 73.8%, while earnings growth is listed as N/A due to the company's negative net income position. Since earnings are negative, they cannot grow faster or slower than revenue in a traditional sense, but the trajectory indicates that revenue expansion is occurring without yet translating into profitability, implying a focus on market penetration and product uptake. The company does not pay dividends, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. This non-dividend status means the company reinvests all available earnings and cash reserves directly into research, development, and commercialization efforts rather than distributing income to shareholders. The overall growth and income profile is defined by aggressive top-line expansion funded by existing cash reserves, with no current distribution of income to investors, prioritizing long-term product lifecycle value over immediate shareholder returns.